Table 4 Association between the distribution of TAB2 rs521845 genotypes and patient’s characteristics
Characteristics | Genotype | OR (95% CI) a | ||||
|---|---|---|---|---|---|---|
TT | TG | GG | Dominant (TT vs. TG/GG) | Recessive (TT/TG vs. GG) | Over-dominant (TT/GG vs. TG) | |
Age | ||||||
<43 | 21 (35.6%) | 26 (44.1%) | 12 (20.3%) | 0.61 0.82 (0.39–1.74) | 0.80 1.13 (0.45–2.80) | 0.48 0.76 (0.36–1.60) |
≥43 | 28 (39.4%) | 28 (39.4%) | 15 (21.1%) | |||
FIGO Stage | ||||||
Stage I | 21 (32.8%) | 30 (46.9%) | 13 (20.3%) | 0.50 0.74 (0.31–1.77) | 0.48 0.67 (0.21–2.09) | 0.89 0.94 (0.40–2.23) |
Stage II-III | 28 (42.4%) | 24 (36.4%) | 14 (21.2%) | |||
Pathological type | ||||||
Squamous | 39 (34.8%) | 48 (42.9%) | 25 (22.3%) | 0.22 0.51 (0.17–1.51) | 0.22 0.38 (0.07–1.97) | 0.79 0.86 (0.27–2.71) |
Others | 10 (55.6%) | 6 (33.3%) | 2 (11.1%) | |||
Tumor differentiation | ||||||
Low | 34 (35.8%) | 40 (42.1%) | 21 (22.1%) | 0.68 0.83 (0.35–1.97) | 0.93 0.95 (0.32–2.81) | 0.73 0.86 (0.36–2.04) |
Mod-High | 15 (42.9%) | 14 (40.0%) | 6 (17.1%) | |||
Lymph node involvement | ||||||
Positive | 11 (40.7%) | 6 (22.2%) | 10 (37.0%) | 0.73 0.82 (0.27–2.50) | 0.009 0.17 (0.04–0.68) | 0.06 3.07 (0.90-10.45) |
Negative | 38 (36.9%) | 48 (46.6%) | 17 (16.5%) | |||
Myometrial invasion | ||||||
>1/2 | 30 (40.5%) | 30 (40.5%) | 14 (18.9%) | 0.63 1.23 (0.53–2.83) | 0.17 2.11 (0.70–6.32) | 0.57 0.79 (0.36–1.77) |
≤1/2 | 19 (33.9%) | 24 (42.9%) | 13 (23.2%) | |||
Peritumoral intravascular cancer emboli | ||||||
Positive | 19 (38.8%) | 19 (38.8%) | 11 (22.4%) | 1.00 1.00 (0.43–2.35) | 0.49 1.49 (0.48–4.62) | 0.59 0.79 (0.33–1.87) |
Negative | 30 (37.0%) | 35 (43.2%) | 16 (19.8%) | |||
Involve others | ||||||
Positive | 18 (40.0%) | 17 (37.8%) | 10 (22.2%) | 0.93 | 0.72 | 0.84 |
Negative | 31 (36.5%) | 37 (43.5%) | 17 (20.0%) | 0.96 (0.42–2.19) | 0.83 (0.30–2.28) | 1.09 (0.48–2.49) |